New research indicates that people who stop using new slimming jabs like Wegovy and Mounjaro tend to recover lost weight far faster than those who stop traditional diet and exercise plans.
Research printed in a leading medical journal points out that while obese people can lose a large proportion of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"People using these treatments need to be aware of the risk of rapid weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting mass within about 18 months.
Weighing Therapies
The analysis, which examined 37 of studies involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
Scientists emphasize that people who shed pounds through diet and exercise typically see a less rapid weight regain—approximately 100 grams monthly—after stopping.
Explaining the Fast Regain
Experts suggest the mechanism of the jabs accounts for the amplified regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in appetite is uncontrolled, making overeating far more likely."
An Ongoing Disease?
Medical guidelines suggest the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, given the significant potential of weight regain, the therapy might need to be life-long.
This view is echoed by drug manufacturers, who note that the findings "highlight the persistent character of obesity," similar to managing conditions like hypertension.
Patient Accounts
Users who have come off the jabs describe a intense return of hunger.
"It felt as if a switch activating and you're instantly starving," recalled a patient.
The struggle is worsened if individuals have not established lasting dietary or behavioural changes during treatment.
Widespread Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is more common among females than men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while these medications are potent tools for shedding pounds, they are not a standalone cure and long-term success hinges on ongoing lifestyle support.
